Advanced Proteome Therapeutics (TSXV:APC.H) ROC % : -612.12% (As of Apr. 2023)

View and export this data going back to 1989. Start your Free Trial

What is Advanced Proteome Therapeutics ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Advanced Proteome Therapeutics's annualized return on capital (ROC %) for the quarter that ended in Apr. 2023 was -612.12%.

As of today (2024-05-26), Advanced Proteome Therapeutics's WACC % is 0.00%. Advanced Proteome Therapeutics's ROC % is 0.00% (calculated using TTM income statement data). Advanced Proteome Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Advanced Proteome Therapeutics ROC % Historical Data

The historical data trend for Advanced Proteome Therapeutics's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Proteome Therapeutics ROC % Chart

Advanced Proteome Therapeutics Annual Data

Trend

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

ROC %

Get a 7-Day Free Trial

-1,090.57

-1,341.44

-505.92

-409.20

-695.80

Advanced Proteome Therapeutics Quarterly Data
	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23
ROC %	Get a 7-Day Free Trial															-269.07	-367.03	-897.44	-812.66	-612.12

Advanced Proteome Therapeutics ROC % Calculation

Advanced Proteome Therapeutics's annualized Return on Capital (ROC %) for the fiscal year that ended in Jul. 2022 is calculated as:

	ROC % (A: Jul. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Jul. 2021 )	+	Invested Capital (A: Jul. 2022 ))	/ count )
=	-1.242 * ( 1 - 0% )	/	( (0.201	+	0.156)	/ 2 )
=	-1.242	/	0.1785
=	-695.80 %

where

	Invested Capital		(A: Jul. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.125	-	1.06	-	( 1.03	-	max(0, 1.252	-	1.116	+	1.03	))
=	0.201

	Invested Capital		(A: Jul. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.823	-	1.475	-	( 0.704	-	max(0, 1.611	-	0.803	+	0.704	))
=	0.156

Advanced Proteome Therapeutics's annualized Return on Capital (ROC %) for the quarter that ended in Apr. 2023 is calculated as:

	ROC % (Q: Apr. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jan. 2023 )	+	Invested Capital (Q: Apr. 2023 ))	/ count )
=	-0.808 * ( 1 - 0% )	/	( (0.223	+	0.041)	/ 2 )
=	-0.808	/	0.132
=	-612.12 %

where

	Invested Capital		(Q: Jan. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.438	-	1.432	-	( 0.392	-	max(0, 1.636	-	0.419	+	0.392	))
=	0.223

	Invested Capital		(Q: Apr. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.085	-	0.073	-	( 0.053	-	max(0, 0.113	-	0.084	+	0.053	))
=	0.041

Note: The Operating Income data used here is four times the quarterly (Apr. 2023) data.

Advanced Proteome Therapeutics (TSXV:APC.H) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Advanced Proteome Therapeutics's WACC % is 0.00%. Advanced Proteome Therapeutics's ROC % is 0.00% (calculated using TTM income statement data). Advanced Proteome Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Advanced Proteome Therapeutics ROC % Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Proteome Therapeutics (TSXV:APC.H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Proteome Therapeutics Corp (TSXV:APC.H) » Definitions » ROC %

Comparable Companies

Traded in Other Exchanges

0E81:Germany

Address

8337 Eastlake Drive, Suite 104, Burnaby, BC, CAN, V5A 4W2

Website

https://www.advancedproteome.com

Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.

Advanced Proteome Therapeutics (TSXV:APC.H) Headlines

No Headlines